[A23-105] Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60
Last updated 21.12.2023
Project no.:
A23-105
Commission:
Commission awarded on 07.11.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to prior disease-modifying antirheumatic therapy
- Patients who have had an inadequate response or who have been intolerant to prior conventional disease-modifying antirheumatic therapy:Unchanged after addendum: added benefit not proven
- Patients who have had an inadequate response or who have been intolerant to prior therapy with biologic disease-modifying antirheumatic drugs:Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-105
Project no. | Title | Status |
---|---|---|
A23-60 | Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-12-21 A G-BA decision was published.